New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
16:02 EDTPCYC, JNJImbruvica shows durable, long-term responses for patients with CLL
Pharmacyclics (PCYC) announced that IMBRUVICA, ibrutinib, will be featured in an oral presentation highlighting long-term responses to treatment, with up to three years of follow up in 132 patients with treatment naive or relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, CLL/SLL. The results from this study will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology, ASCO, on June 2, 2014, at 11:33 a.m. CT. This release corresponds to abstract 7014. IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ)."These results suggest responses to IMBRUVICA are exceptionally durable in patients with CLL with a median observation period past 30 months," said Dr. Susan O'Brien*, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX. "IMBRUVICA is very well tolerated. We are especially encouraged to see that patients showed durable responses regardless of their treatment history."
News For PCYC;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
07:27 EDTJNJJohnson & Johnson drug business likely to remain resilient, says Wells Fargo
Subscribe for More Information
July 29, 2015
12:17 EDTJNJMedivation plummets after Cowen highlights slowing Xtandi trends
Subscribe for More Information
11:23 EDTJNJMedivir says Janssen's Alios BIopharma starts Phase I AL-704 trial
Subscribe for More Information
July 28, 2015
07:05 EDTJNJMacroGenics reports MGD011 advances into clinical development
Subscribe for More Information
July 27, 2015
10:40 EDTJNJLeerink major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
July 23, 2015
17:51 EDTJNJJanssen submits sNDA to update label for Olysio
Subscribe for More Information
July 22, 2015
10:15 EDTJNJThoratec downgraded to Market Perform from Outperform at Northland
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use